Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
The blockade of PD‐1/PD‐L1, which serves to “release the brake” of tumor immunity, represents a promising approach for treating various malignancies. However, the systemic immune‐related side effects significantly undermine its therapeutic efficacy. To address this dilemma, a photoactivatable and biocompatible prodrug cBMS‐1 based on the concept of photopharmacology is reported. The prodrug exhibits negligible toxicity but exerts effective PD‐1/PD‐L1 axis inhibition upon light irradiation, holding promising potential to achieve local activation of immune responses in clinical settings.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization ; day:16 ; month:05 ; year:2022 ; extent:8
Advanced nanoBiomed research ; (16.05.2022) (gesamt 8)
- Urheber
-
Liu, Yuwei
Long, Kaiqi
Kang, Weirong
Wang, Tianyi
Wang, Weiping
- DOI
-
10.1002/anbr.202200017
- URN
-
urn:nbn:de:101:1-2022051615102120864876
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
26.05.3215, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Liu, Yuwei
- Long, Kaiqi
- Kang, Weirong
- Wang, Tianyi
- Wang, Weiping
Ähnliche Objekte (12)
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition
High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers
Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition
High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers
Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition
High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers
Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1